Home › Crohn's Disease › Louisiana
Pag-aaral pangklinika para sa Crohn's Disease sa Louisiana
11 pag-aaral para sa Crohn's Disease ang naghahanap ng mga kalahok sa mga site sa Louisiana.
Mga Lungsod sa Louisiana
- Lafayette7 pag-aaral
- Metairie5 pag-aaral
- Shreveport3 pag-aaral
- New Orleans3 pag-aaral
- Monroe3 pag-aaral
- Baton Rouge3 pag-aaral
Opisyal na teksto ng pag-aaral (English)
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Group and Endocenter: Mandeville, la /ID# 284186, Mandeville
- Metropolitan Gastroenterology Associates - Metairie /ID# 283922, Metairie
- Willis-Knighton Medical Center /ID# 280572, Shreveport
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Baton Rouge General Medical Center - Bluebonnet Campus, Baton Rouge
- Combined Gastro LLC, Lafayette
- GI Alliance, Metairie
Nagre-recruitPhase 4
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06581328A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
- Delta Research Partners, LLC, West Monroe
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07196722Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Care Access - New Iberia, New Iberia
- Louisiana Research Center, Shreveport
Nagre-recruitPhase 3
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Baton Rouge-Site Number: 8400129, Baton Rouge
- Tandem Intermediate, LLC - Houma-Site Number: 8400034, Houma
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128, Mandeville
- at 4 pa
Nagre-recruitPhase 3
Edad 16 hanggang 80 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Baton Rouge-Site Number: 8400129, Baton Rouge
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128, Mandeville
- GI Alliance - Metairie-Site Number: 8400124, Metairie
- at 1 pa
Nagre-recruitPhase 3
Edad 16 hanggang 80 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07184944A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Tandem Clinical Research, Houma
Nagre-recruitPhase 2
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06226883A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- GI Alliance, Metairie
- Tulane University, New Orleans
Nagre-recruitPhase 4
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07577843A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Lafayette
- Mirador Therapeutics Selected Site, Marrero
- Mirador Therapeutics Selected Site, Shreveport
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Mar 12, 2026 · NCT07113522Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.